Vivos Therapeutics, Inc. / Estimates

    Fiscal Year Revenue Net income Net margin Free cash flow FCF margin
    (estimated) €21.39M +52.0% -€11.20M -22.1% -52.4% +0.50 pp N/A N/A
    (estimated) €14.07M +9.8% -€14.38M +51.4% -102.2% -0.28 pp N/A N/A
    €12.82M +8.9% -€9.50M -18.0% -74.1% +0.24 pp -€10.34M +8.8% -80.7% +0.00087 pp
    €11.77M -13.9% -€11.59M -40.1% -98.4% +0.43 pp -€9.50M -40.3% -80.7% +0.36 pp
    €13.67M -5.1% -€19.33M +11.7% -141.4% -0.21 pp -€15.92M +39.9% -116.5% -0.37 pp
    €14.40M +29.2% -€17.31M +130.0% -120.2% -0.53 pp -€11.38M +139.9% -79.0% -0.36 pp
    €11.14M +14.7% -€7.53M -19.0% -67.5% +0.28 pp -€4.74M +7.7% -42.6% +0.028 pp
    €9.72M +200.4% -€9.29M +27.5% -95.6% +1.3 pp -€4.41M +27.1% -45.3% +0.62 pp
    €3.23M -€7.29M -225.3% -€3.47M -107.1%

    Notifications